I am please to present a special guest blog post from Duncan Emerton, PhD, the author of The Biosimilarz Blog (you can also find him on Twitter @Biosimilarz). Dr. Emerton has extensive experience in the pharmaceutical industry and currently serves as Senior Director, Syndicated Insights & Analysis for FirstWord Pharma. Biosimilars are an occasional topic of coverage here at BiotechDueDiligence so I invited Duncan to offer his reflections for readers, and he was gracious enough to say yes!
You can find Dr. Emerton's complete Bio here, and be sure to follow Biosimilarz via blog or Twitter. Duncan's blog is one of many new additional to my Biotech Links page - be sure to check them all out if you have not done so recently.
Continue reading for Dr. Emerton's reflections on 2013 as well a look ahead to 2014, and be sure to leave your own biosimilars predictions (good or bad) for 2014 in the comments section or via Twitter.
-Andrew
Note: this blog entry is entirely the work and personal opinion of Dr. Duncan Emerton. Please read and understand my customary BiotechDueDilgience Disclaimer as well as the author's Disclaimer below.
You can find Dr. Emerton's complete Bio here, and be sure to follow Biosimilarz via blog or Twitter. Duncan's blog is one of many new additional to my Biotech Links page - be sure to check them all out if you have not done so recently.
Continue reading for Dr. Emerton's reflections on 2013 as well a look ahead to 2014, and be sure to leave your own biosimilars predictions (good or bad) for 2014 in the comments section or via Twitter.
-Andrew
Note: this blog entry is entirely the work and personal opinion of Dr. Duncan Emerton. Please read and understand my customary BiotechDueDilgience Disclaimer as well as the author's Disclaimer below.
RSS Feed
